Hybrid <i>In Silico</i> Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants
Sankalp Jain(National Institutes of Health), Alexey Zakharov(Imperial College London), Jun Choe(National Institutes of Health), Matthew D. Hall(National Institutes of Health), Bolormaa Baljinnyam(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Daniel C. Talley(National Institutes of Health), Ganesha Rai(National Institutes of Health), Anton Simeonov(National Institutes of Health), Wei Zhu(Guangzhou University of Chinese Medicine), Min Shen(Kaili University), Miao Xu(National Institutes of Health), Catherine Z. Chen(National Institutes of Health), Xin Hu(Discovery Institute), Quinlin Hanson(National Institutes of Health)
Cited by 16
Related Papers
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|391
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Erratum: Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|327